Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Clinical Immunology · Combined Immunodeficiency With Granulomas

The Biology and Genetics of Combined Immunodeficiency

At a Glance

Combined immunodeficiency with granulomas often involves partly working RAG1, RAG2, or Artemis genes, so the body makes fewer varied T and B cells. Doctors combine blood tests, immune-cell studies, a test that rules out chronic granulomatous disease, and genetic testing to evaluate the condition.

Understanding the biology of combined immunodeficiency with granulomas requires looking at how the immune system “learns” to recognize germs. In a healthy body, the immune system acts like a library with millions of different books, each representing a way to fight a specific virus or bacteria. In this condition, the process that creates these books is impaired [1][2].

Shuffling the Deck: V(D)J Recombination

To create a diverse immune system, your body uses a process called V(D)J recombination [3]. Think of your immune cell genes as a deck of cards. To make a unique receptor that can recognize a specific germ, the body “shuffles” and “cuts” these gene segments (named Variable, Diversity, and Joining) and pastes them back together in new combinations [4][5].

Two main players make this possible:

  • RAG1 and RAG2: These act like the “scissors.” They identify the right spots on the DNA and make the necessary cuts [3].
  • Artemis (DCLRE1C): This acts like the “opener.” After the cuts are made, Artemis helps open the DNA ends so they can be joined back together into a new, unique sequence [3][6].

The “Leaky” Nature of Hypomorphic Mutations

The key difference between this condition and its more severe cousin, SCID (Severe Combined Immunodeficiency), lies in how well these “scissors” and “openers” work.

  • Total Loss of Function (SCID): If the RAG or Artemis genes don’t work at all, no “shuffling” happens. The body cannot make any T or B cells, leading to a complete lack of immunity from birth [7][8].
  • Partial Function: In this spectrum, the genetic variants are hypomorphic (or “leaky”). This means the scissors are dull, or the opener only works partially [6][8]. Some shuffling still happens, so some T and B cells are made. However, the “deck” is not shuffled well. This results in a restricted repertoire—a library with very little diversity [1][9].

Because the immune system is limited to only a few types of cells, it often misses common germs (deficiency) while accidentally attacking the body’s own tissues (autoimmunity) [10][11].

Distinguishing This Condition from Others

Because it involves both infections and granulomas, it can look like other rare immune conditions. Your doctor must distinguish it from:

  • Chronic Granulomatous Disease (CGD): While this condition is a defect in lymphocyte (T and B cell) development and receptor diversity, CGD impairs the ability of phagocytes (like neutrophils) to produce the oxidative “burst” needed to kill germs [12][13]. Both can cause granulomas, but they are fundamentally different biological problems [14][15].
  • Activated PI3K-Delta Syndrome (APDS): APDS shares some symptoms like frequent infections and autoimmunity, but it is caused by different mechanisms. APDS1 usually results from a gain-of-function mutation in the PIK3CD gene, whereas APDS2 is often caused by variants in PIK3R1 that still result in an overactive signaling pathway [16][17][18].

Diagnostic Workup

To confirm a diagnosis, a specialist will typically integrate findings from multiple tests. A negative or unavailable test does not necessarily exclude the diagnosis:

  1. Complete Blood Count (CBC) with Differential: To check the total number of white blood cells and lymphocytes [19].
  2. Advanced Flow Cytometry: This looks specifically at naïve T cells. A very low number of “naïve” (untrained) cells is a major clue that the development process isn’t working properly [9][20].
  3. TREC and KREC Levels: These are episomal products (circular pieces of DNA) created during T-cell and B-cell receptor rearrangement. Low values indicate reduced output from the thymus or bone marrow, though they can be affected by other factors [21][9].
  4. TCR Repertoire Sequencing: This test measures the diversity of your T-cell library. In this condition, this will often show a “skewed” or “restricted” pattern [1][22].
  5. DHR (Dihydrorhodamine) Test: This is the gold standard to rule out CGD by checking if your cells can create the necessary “oxidative burst” to kill germs [14][23].
  6. Genetic Panel: A targeted sequencing test that looks for mutations in RAG1, RAG2, DCLRE1C (Artemis), and other related genes [24][25].

Once these tests are combined, your medical team can build a precise map of how your immune system is functioning and tailor your treatment accordingly.

Common questions in this guide

What is combined immunodeficiency with granulomas?
It is an inherited immune disorder in which partial defects in the genes that help build T and B cells reduce the variety of germ-fighting cells. People may have recurrent or unusual infections, granulomas, and autoimmune problems.
How do RAG1, RAG2, and Artemis changes affect immunity?
These proteins help rearrange DNA segments so T and B cells can make varied receptors that recognize germs. Partly working variants may allow some immune cells to develop, but the range of receptors remains limited.
How is this condition different from SCID?
SCID can result when RAG or Artemis function is completely lost, preventing normal development of T and B cells. Combined immunodeficiency with granulomas often involves partial, or hypomorphic, function, so some cells are produced but their diversity and protection are limited.
What tests help diagnose combined immunodeficiency with granulomas?
The workup may include a complete blood count, flow cytometry for naive T cells, TREC and KREC levels, T-cell receptor repertoire sequencing, a DHR test, and a genetic panel that includes RAG1, RAG2, and DCLRE1C. Doctors interpret these results together, and one negative or unavailable test does not necessarily rule out the condition.
Why is a DHR test used when granulomas are present?
The DHR test measures whether phagocytes can produce the oxidative burst needed to kill certain germs. It helps rule out chronic granulomatous disease, which can also cause granulomas but affects a different part of the immune system.
What does a restricted T-cell receptor repertoire mean?
It means the T-cell population has fewer distinct receptors than expected, limiting the range of germs it can recognize. T-cell receptor repertoire sequencing can identify this pattern alongside other immune and genetic results.

Get notified when new evidence is published on Combined immunodeficiency with granulomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (25)
  1. 1

    Characterization of T and B cell repertoire diversity in patients with RAG deficiency.

    Lee YN, Frugoni F, Dobbs K, et al.

    Science immunology 2016; (1(6)) doi:10.1126/sciimmunol.aah6109.

    PMID: 28783691
  2. 2

    DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency.

    Volk T, Pannicke U, Reisli I, et al.

    Human molecular genetics 2015; (24(25)):7361-72 doi:10.1093/hmg/ddv437.

    PMID: 26476407
  3. 3

    An Update on Inborn Errors of V(D)J Recombination.

    Schim van der Loeff I, Ahuja M, Chen R, et al.

    Physiology (Bethesda, Md.) 2026; (41(6)):0 doi:10.1152/physiol.00004.2026.

    PMID: 41902554
  4. 4

    Autoinhibition of the Nuclease ARTEMIS Is Mediated by a Physical Interaction between Its Catalytic and C-terminal Domains.

    Niewolik D, Peter I, Butscher C, Schwarz K

    The Journal of biological chemistry 2017; (292(8)):3351-3365 doi:10.1074/jbc.M116.770461.

    PMID: 28082683
  5. 5

    Recent advances in the study of immunodeficiency and DNA damage response.

    Morio T

    International journal of hematology 2017; (106(3)):357-365 doi:10.1007/s12185-017-2263-8.

    PMID: 28550350
  6. 6

    Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency.

    Felgentreff K, Lee YN, Frugoni F, et al.

    The Journal of allergy and clinical immunology 2015; (136(1)):140-150.e7.

    PMID: 25917813
  7. 7

    Recombination activity of human recombination-activating gene 2 (RAG2) mutations and correlation with clinical phenotype.

    Tirosh I, Yamazaki Y, Frugoni F, et al.

    The Journal of allergy and clinical immunology 2019; (143(2)):726-735 doi:10.1016/j.jaci.2018.04.027.

    PMID: 29772310
  8. 8

    Phenotypical heterogeneity in RAG-deficient patients from a highly consanguineous population.

    Meshaal SS, El Hawary RE, Abd Elaziz DS, et al.

    Clinical and experimental immunology 2019; (195(2)):202-212 doi:10.1111/cei.13222.

    PMID: 30307608
  9. 9

    RAG1 deficiency may present clinically as selective IgA deficiency.

    Kato T, Crestani E, Kamae C, et al.

    Journal of clinical immunology 2015; (35(3)):280-8 doi:10.1007/s10875-015-0146-4.

    PMID: 25739914
  10. 10

    Omenn Syndrome and DNA recombination defects.

    Yachie A

    Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 2017; (40(3)):179-189 doi:10.2177/jsci.40.179.

    PMID: 28747605
  11. 11

    Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.

    Walter JE, Rosen LB, Csomos K, et al.

    The Journal of clinical investigation 2015; (125(11)):4135-48.

    PMID: 26457731
  12. 12

    Hematologically important mutations: The autosomal forms of chronic granulomatous disease (third update).

    Roos D, van Leeuwen K, Hsu AP, et al.

    Blood cells, molecules & diseases 2021; (92()):102596 doi:10.1016/j.bcmd.2021.102596.

    PMID: 34547651
  13. 13

    Chronic granulamatous disease: Two decades of experience from a paediatric immunology unit in a country with high rate of consangineous marriages.

    Kutukculer N, Aykut A, Karaca NE, et al.

    Scandinavian journal of immunology 2019; (89(2)):e12737 doi:10.1111/sji.12737.

    PMID: 30506560
  14. 14

    NAPDH Oxidase-Specific Flow Cytometry Allows for Rapid Genetic Triage and Classification of Novel Variants in Chronic Granulomatous Disease.

    Sacco KA, Smith MJ, Bahna SL, et al.

    Journal of clinical immunology 2020; (40(1)):191-202 doi:10.1007/s10875-019-00712-6.

    PMID: 31813112
  15. 15

    Clinical presentation, diagnosis, and treatment of chronic granulomatous disease.

    Staudacher O, von Bernuth H

    Frontiers in pediatrics 2024; (12()):1384550 doi:10.3389/fped.2024.1384550.

    PMID: 39005504
  16. 16

    Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.

    Redenbaugh V, Coulter T

    Frontiers in pediatrics 2021; (9()):702872 doi:10.3389/fped.2021.702872.

    PMID: 34422726
  17. 17

    Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

    Coulter TI, Chandra A, Bacon CM, et al.

    The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.

    PMID: 27555459
  18. 18

    Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

    Wentink M, Dalm V, Lankester AC, et al.

    Clinical immunology (Orlando, Fla.) 2017; (176()):77-86 doi:10.1016/j.clim.2017.01.004.

    PMID: 28104464
  19. 19

    Heterogeneity in RAG1 and RAG2 deficiency: 35 cases from a single-centre.

    Karaatmaca B, Cagdas D, Esenboga S, et al.

    Clinical and experimental immunology 2024; (215(2)):160-176 doi:10.1093/cei/uxad110.

    PMID: 37724703
  20. 20

    TREC and KREC profiling as a representative of thymus and bone marrow output in patients with various inborn errors of immunity.

    Dasouki M, Jabr A, AlDakheel G, et al.

    Clinical and experimental immunology 2020; (202(1)):60-71 doi:10.1111/cei.13484.

    PMID: 32691468
  21. 21

    EuroFlow Standardized Approach to Diagnostic Immunopheneotyping of Severe PID in Newborns and Young Children.

    Kalina T, Bakardjieva M, Blom M, et al.

    Frontiers in immunology 2020; (11()):371 doi:10.3389/fimmu.2020.00371.

    PMID: 32265901
  22. 22

    A High-Throughput Sequencing Strategy for Clinical Repertoire Profiling of T Cell Receptor Beta Chain: Development and Reference Values Across Healthy Adults, Paediatrics, and Cord Blood Units.

    Enrich E, Antón-Iborra M, Hobeich C, et al.

    International journal of molecular sciences 2025; (26(19)) doi:10.3390/ijms26199590.

    PMID: 41096855
  23. 23

    Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine-123 assay: Lessons from a large monocentric cohort.

    Oiuna L, Tatiana V, Daria Y, et al.

    Cytometry. Part B, Clinical cytometry 2026; (110(3)):201-220 doi:10.1002/cytob.70014.

    PMID: 41693676
  24. 24

    Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing.

    Yu H, Zhang VW, Stray-Pedersen A, et al.

    The Journal of allergy and clinical immunology 2016; (138(4)):1142-1151.e2 doi:10.1016/j.jaci.2016.05.035.

    PMID: 27484032
  25. 25

    Asymptomatic Infant With Atypical SCID and Novel Hypomorphic RAG Variant Identified by Newborn Screening: A Diagnostic and Treatment Dilemma.

    Chitty-Lopez M, Westermann-Clark E, Dawson I, et al.

    Frontiers in immunology 2020; (11()):1954 doi:10.3389/fimmu.2020.01954.

    PMID: 33117328

This page explains the biology, genetics, and diagnostic tests associated with combined immunodeficiency with granulomas for informational purposes only and does not constitute medical advice. An immunologist or genetics specialist should interpret your or your child's results.

Guide contents Combined immunodeficiency with granulomatosis
Research & Literature
02 Symptoms, Granulomas, and Warning Signs 04 Understanding Your Granuloma Biopsies